Procysbi - summary of medicine characteristics

1. NAME OF THE MEDICINAL PRODUCT

PROCYSBI 25 mg gastro-resistant hard capsules PROCYSBI 75 mg gastro-resistant hard capsules

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

PROCYSBI 25 mg hard capsule

Each hard capsule contains 25 mg of cysteamine (as mercaptamine bitartrate).

PROCYSBI 75 mg hard capsule

Each hard capsule contains 75 mg of cysteamine (as mercaptamine bitartrate).

For the full list of excipients, see section 6.1.

3. PHARMACEUTICAL FORM

Gastro-resistant hard capsule.

PROCYSBI 25 mg hard capsule

Light blue size 3 hard capsules imprinted “25 mg” in white ink and a light blue cap imprinted with “PRO” in white ink.

PROCYSBI 75 mg hard capsule

Light blue size 0 hard capsules imprinted “75 mg” in white ink and a dark blue cap imprinted with “PRO” in white ink.

4. CLINICAL PARTICULARS4.1 Therapeutic indications

PROCYSBIis indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.

4.2 Posology and method of administration

PROCYSBI treatment should be initiated under the supervision of a physician experienced in the treatment of cystinosis.

Cysteamine therapy must be initiated promptly once the diagnosis is confirmed (i.e., increased WBC cystine) to achieve maximum benefit.

Posology

White blood cell (WBC) cystine concentration may for instance be measured by a number of different techniques such as specific WBC subsets (e.g., granulocyte assay) or the mixed leukocyte assay with each assay having different target values. Healthcare professionals should refer to the assay-specific therapeutic targets provided by individual testing laboratories when making decisions regarding diagnosis and PROCYSBI dosing for cystinosis patients. For example the therapeutic goal is to maintain a WBC cysteine level < 1 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay), 30 min after dosing For patients adherent to a stable dose of PROCYSBI, and who do not have easy access to an adequate facility for measuring their WBC cystine, the goal of therapy should be to maintain plasma cysteamine concentration > 0.1 mg/L, 30 min after dosing.

Measurement timing: PROCYSBI should be administered every 12 hours. The determination of WBC cystine and/or plasma cysteamine must be obtained 12.5 hours after the evening dose the day before, and therefore 30 minutes after the following morning dose is given.

Transferring patients from immediate-release cysteamine bitartrate hard capsules

Patients with cystinosis taking immediate-release cysteamine bitartrate may be transferred to a total daily dose of PROCYSBI equal to their previous total daily dose of immediate-release cysteamine bitartrate. Total daily dose should be divided by two and administered every 12 hours. The maximum recommended dose of cysteamine is 1.95 g/m2/day. The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.4).

Patients being transferred from immediate-release cysteamine bitartrate to PROCYSBI should have their WBC cystine levels measured in 2 weeks, and thereafter every 3 months to assess optimal dose as described above.

Newly diagnosed adult patients

Newly diagnosed adult patients should be started on 1/6 to 1/4 of the targeted maintenance dose of PROCYSBI. The targeted maintenance dose is 1.3 g/m2/day, in two divided doses, given every 12 hours. The dose should be raised if there is adequate tolerance and the WBC cystine level remains > 1 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay). The maximum recommended dose of cysteamine is 1.95 g/m2/day. The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.4).

The target values provided in the SmPC are obtained from using the mixed leucocyte assay. It should be noted that therapeutic targets for cystine depletion are assay-specific and different assays have specific treatment targets. Therefore, healthcare professionals should refer to the assay-specific therapeutic targets provided by individual testing laboratories.

Newly diagnosed paediatric population

The targeted maintenance dose of 1.3 g/m2/day can be approximated according to the following table, which takes surface area as well as weight into consideration.

Weight in kilograms	Recommended dose in mg Every 12 hours*
0–5	200
5–10	300
11–15	400
16–20	500
21–25	600
26–30	700
31–40	800
41–50	900
> 50	1000

* Higher dose may be required to achieve target WBC cystine concentration. The use of doses higher than 1.95 g/m2/day is not recommended.

Special populations

Patients with poor tolerability

Patients with poorer tolerability still receive significant benefit if white blood cell cystine levels are below 2 nmol hemicystine/mg protein (when measured using the mixed leukocyte assay). The cysteamine dose can be increased to a maximum of 1.95 g/m2/day to achieve this level. The dose of 1.95 g/m2/day of immediate-release cysteamine bitartrate has been associated with an increased rate of withdrawal from treatment due to intolerance and an increased incidence of adverse events. If cysteamine is initially poorly tolerated due to gastrointestinal (GI) tract symptoms or transient skin rashes, therapy should be temporarily stopped, then re-instituted at a lower dose and gradually increased to the appropriate dose (see section 4.4).

Patients with renal impairment

Dose adjustment is not normally required; however, WBC cystine levels should be monitored.

Patients with hepatic impairment

Dose adjustment is not normally required; however, WBC cystine levels should be monitored.

Method of administration

This medicinal product can be administered by swallowing the intact capsules as well as sprinkling the capsule contents (enteric coated beads) on food or delivery through a gastric feeding tube.

Do not crush or chew capsules or capsule contents.

Missed doses

If a dose is missed, it should be taken as soon as possible. If it is within four hours of the next dose, skip the missed dose and go back to the regular dosing schedule. Do not double the dose.

Administration with food

Cysteamine bitartrate can be administered with an acidic fruit juice or water.

Cysteamine bitartrate should not be administered with food rich in fat or proteins, or with frozen food like ice-cream. Patients should try to consistently avoid meals and dairy products for at least 1 hour before and 1 hour after PROCYSBI dosing. If fasting during this period is not possible, it is acceptable to eat only a small amount (~ 100 grams) of food (preferentially carbohydrates) during the hour before and after PROCYSBI administration. It is important to dose PROCYSBI in relation to food intake in a consistent and reproducible way over time (see section 5.2)

In paediatric patients who are at risk of aspiration, aged approximately 6 years and under, the hard capsules should be opened and the content sprinkled on food or liquid listed below.

Sprinkling on food

Capsules for either the morning or evening dose should be opened and the contents sprinkled onto approximately 100 grams of apple sauce or berry jelly. Gently stir the contents into the soft food, creating a mixture of cysteamine granules and food. The entire amount of the mixture should be eaten. This may be followed by 250 mL of an acceptable acidic liquid – fruit juice (e.g., orange juice or any acidic fruit juice) or water. The mixture must be eaten within 2 hours after preparation and must be refrigerated from the time of preparation to the time of administration.

Administering through feeding tubes

Capsules for either the morning or evening dose should be opened and the contents sprinkled onto approximately 100 grams of apple sauce or berry jelly. Gently stir the contents into the soft food, creating a mixture of cysteamine granules and the soft food. The mixture should then be administered via gastrostomy tube, nasogastric tube or gastrostomy-jejunostomy tube. The mixture must be administered within 2 hours after preparation and may be refrigerated from the time of preparation to the time of administration.

Sprinkling in orange juice or any acidic fruit juice or water

Capsules for either the morning or evening dose should be opened and the contents sprinkled into 100 to 150 mL of acidic fruit juice or water. Dose administration options are provided below:

• • Option 1 / Syringe: Mix gently for 5 minutes, then aspirate the mixture of cysteamine granules and acidic fruit juice or water into a dosing syringe.
• • Option 2 / Cup: Mix gently for 5 minutes in a cup or shake gently for 5 minutes in a covered cup (e.g., “sippy” cup). Drink the mixture of cysteamine granules and acidic fruit juice or water.

The mixture must be administered (drunk) within 30 minutes after preparation and must be refrigerated from the time of preparation to the time of administration.

4.3 Contraindications

• • Hypersensitivity to the active substance, any form of cysteamine (mercaptamine), or to any of the excipients listed in section 6.1.
• • Hypersensitivity to penicillamine.
• • Breast-feeding.

4.4 Special warnings and precautions for use

The use of doses higher than 1.95 g/m2/day is not recommended (see section 4.2).

Oral cysteamine has not been shown to prevent eye deposition of cystine crystals. Therefore, where cysteamine ophthalmic solution is used for that purpose, its usage should continue.

If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered and the patient must be advised of the possible teratogenic risk of cysteamine (see section 4.6).

Intact capsules of PROCYSBI should not be administered to children under the age of approximately 6 years due to risk of aspiration (see section 4.2).

Dermatological

There have been reports of serious skin lesions in patients treated with high doses of immediate-release cysteamine bitartrate or other cysteamine salts that have responded to cysteamine dose reduction. Physicians should routinely monitor the skin and bones of patients receiving cysteamine.

If skin or bone abnormalities appear, the dose of cysteamine should be reduced or stopped. Treatment may be restarted at a lower dose under close supervision, and then slowly titrated to the appropriate therapeutic dose (see sections 4.2). If a severe skin rash develops such as erythema multiforme bullosa or toxic epidermal necrolysis, cysteamine should not be re-administered (see sections 4.8).

Gastrointestinal

GI ulceration and bleeding have been reported in patients receiving immediate-release cysteamine bitartrate. Physicians should remain alert for signs of ulceration and bleeding and should inform patients and/or guardians about the signs and symptoms of serious GI toxicity and what steps to take if they occur.

GI tract symptoms including nausea, vomiting, anorexia and abdominal pain have been associated with cysteamine.

Strictures of the ileo-caecum and large bowel (fibrosing colonopathy) was first described in cystic fibrosis patients who were given high doses of pancreatic enzymes in the form of tablets with an enteric coating of methacrylic acid – ethyl acrylate copolymer (1:1), one of the excipients in PROCYSBI. As a precaution, unusual abdominal symptoms or changes in abdominal symptoms should be medically assessed to exclude the possibility of fibrosing colonopathy.

Central Nervous System (CNS)

CNS symptoms such as seizures, lethargy, somnolence, depression, and encephalopathy have been associated with cysteamine. If CNS symptoms develop, the patient should be carefully evaluated and the dose adjusted as necessary. Patients should not engage in potentially hazardous activities until the effects of cysteamine on mental performance are known (see section 4.7).

Leukopenia and abnormal liver function

Cysteamine has occasionally been associated with reversible leukopenia and abnormal liver function. Therefore, blood counts and liver function should be monitored.

Benign intracranial hypertension

There have been reports of benign intracranial hypertension (or pseudotumor cerebri (PTC)) and/or papilledema associated with cysteamine bitartrate treatment that has resolved with the addition of diuretic therapy (post-marketing experience with the immediate-release cysteamine bitartrate). Physicians should instruct patients to report any of the following symptoms: headache, tinnitus, dizziness, nausea, diplopia, blurred vision, loss of vision, pain behind the eye or pain with eye movement. A periodic eye examination is needed to identify this condition early and timely treatment should be provided when it occurs to prevent vision loss.

Important information about some of the excipients of PROCYSBI

This medicinal product contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially sodium-free.

4.5 Interaction with other medicinal products and other forms of interaction

It cannot be excluded that cysteamine is a clinically relevant inducer of CYP enzymes, inhibitor of P-gp and BCRP at the intestinal level and inhibitor of liver uptake transporters (OATP1B1, OATP1B3 and OCT1).

Co-administration with electrolyte and mineral replacement

Cysteamine can be administered with electrolyte (except bicarbonate) and mineral replacements necessary for management of Fanconi syndrome as well as vitamin D and thyroid hormone. Bicarbonate should be administered at least one hour before or one hour after PROCYSBI to avoid potential earlier release of cysteamine.

Indomethacin and cysteamine have been used simultaneously in some patients. In cases of patients with kidney transplants, anti-rejection treatments have been used with cysteamine.

Co-administration of the proton pump inhibitor omeprazole and PROCYSBI in vivo showed no effects on cysteamine bitartrate exposure.

4.6 Fertility, pregnancy and lactation

Pregnancy

There is no adequate data from the use of cysteamine in pregnant women. Studies in animals have shown reproductive toxicity, including teratogenesis (see section 5.3). The potential risk for humans is unknown. The effect on pregnancy of untreated cystinosis is also unknown. Therefore, cysteamine bitartrate should not be used during pregnancy, particularly during the first trimester, unless clearly necessary (see section 4.4).

If a pregnancy is diagnosed or planned, the treatment should be carefully reconsidered and the patient must be advised of the possible teratogenic risk of cysteamine.

Breast-feeding

Cysteamine excretion in human milk is unknown. However, due to the results of animal studies in breast-feeding females and neonates (see section 5.3), breast-feeding is contra-indicated in women taking PROCYSBI (see section 4.3).

Fertility

Effects on fertility have been seen in animal studies (see section 5.3). Azoospermia has been reported in male cystinosis patients.

4.7 Effects on ability to drive and use machines

Cysteamine has minor or moderate influence on the ability to drive and use machines.

Cysteamine may cause drowsiness. When starting therapy, patients should not engage in potentially hazardous activities until the effects of the medicinal product on each individual are known.

4.8 Undesirable effects

Summary of the safety profile

For the immediate-release formulation of cysteamine bitartrate, approximately 35% of patients can be expected to experience adverse reactions. These mainly involve the gastrointestinal and central nervous systems. When these reactions appear at the initiation of cysteamine therapy, temporary suspension and gradual reintroduction of treatment may be effective in improving tolerance.

In clinical studies with healthy volunteers, the most frequent adverse reactions were very common GI symptoms (16%) and occurred primarily as single episodes that were mild or moderate in severity.

The adverse reactions profile for healthy subjects was similar to the adverse reactions profile in patients relative to GI disorders (diarrhoea and abdominal pain).

Tabulated list of adverse reactions

The frequency of adverse reactions is defined using the following convention: very common (>1/10); common (>1/100 to <1/10); uncommon (>1/1,000 to <1/100); rare (>1/10,000 to <1/1,000); very rare (<1/10,000) and not known (cannot be estimated from available data).

Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness:

MedDRA system organ class	Frequency: adverse reaction
Blood and lymphatic system disorders	Uncommon: Leukopenia
Immune system disorders	Uncommon: Anaphylactic reaction
Metabolism and nutrition disorders	Very common: Anorexia
Psychiatric disorders	Uncommon: Nervousness, hallucination
Nervous system disorders	Common: Headache, encephalopathy
	Uncommon: Somnolence, convulsions
Gastrointestinal disorders	Very common: Vomiting, nausea, diarrhoea
	Common: Abdominal pain, breath odour, dyspepsia, gastroenteritis
	Uncommon: Gastrointestinal ulcer
Skin and subcutaneous tissue disorders	Common: Skin odour abnormal, rash
	Uncommon: Hair colour changes, skin striae, skin fragility (molluscoid pseudotumour on elbows)
Musculoskeletal and connective tissue disorders	Uncommon: Joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture, scoliosis.

Renal and urinary disorders	Uncommon: Nephrotic syndrome
General disorders and administration site conditions	Very common: Lethargy, pyrexia
	Common: Asthenia
Investigations	Common: Liver function tests abnormal

Description of selected adverse reactions

Clinical studies experience with PROCYSBI

In clinical studies comparing PROCYSBI to the immediate-release cysteamine bitartrate, one third of the patients exhibited very common GI disorders (nausea, vomiting, abdominal pain). Common nervous system disorders (headache, somnolence and lethargy) and common general disorders (asthenia) were also seen.

Post-marketing experience with immediate-release cysteamine bitartrate

Benign intracranial hypertension (or pseudotumor cerebri (PTC)) with papilledema; skin lesions, molluscoid pseudotumors, skin striae, skin fragility; joint hyperextension, leg pain, genu valgum, osteopenia, compression fracture and scoliosis have been reported with immediate-release cysteamine bitartrate (see section 4.4).

Two cases of nephrotic syndrome have been reported within 6 months of starting therapy with progressive recovery after treatment discontinuation. Histology showed a membranous glomerulonephritis of the renal allograft in one case and hypersensitivity interstitial nephritis in the other.

A few cases of Ehlers-Danlos-like syndrome on elbows have been reported in children chronically treated with high doses of different cysteamine preparations (cysteamine chlorhydrate or cystamine or cysteamine bitartrate) mostly above the maximal dose 1.95 g/m2/day. In some cases, these skin lesions were associated with skin striae and bone lesions first seen during an X-ray examination. Bone disorders reported were genu valgum, leg pain and hyperextensive joints, osteopenia, compression fractures, and scoliosis. In the few cases where histopathological examination of the skin was performed, the results suggested angioendotheli­omatosis. One patient subsequently died of acute cerebral ischemia with marked vasculopathy. In some patients, the skin lesions on elbows regressed after immediate-release cysteamine dose reduction (see section 4.4).

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.

4.9 Overdose

An overdose of cysteamine may cause progressive lethargy.

Should overdosing occur, the respiratory and cardiovascular systems should be supported appropriately. No specific antidote is known. It is not known if cysteamine is removed by haemodialysis.

5. PHARMACOLOGICAL PROPERTIES5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other alimentary tract and metabolism product, ATC code: A16AA04.

Cysteamine is the simplest stable aminothiol and a degradation product of the amino acid cysteine. Cysteamine participates within lysosomes in a thiol-disulfide interchange reaction converting cystine into cysteine and cysteine-cysteamine mixed disulfide, both of which can exit the lysosome in patients with cystinosis.

Normal individuals and persons heterozygous for cystinosis have white blood cell cystine levels of < 0.2 and usually below 1 nmol hemicystine/mg protein, respectively, when measured using the mixed leukocyte assay. Individuals with cystinosis have elevations of WBC cystine above 2 nmol hemicystine/mg protein.

WBC cystine is monitored in these patients to determine adequacy of dosing, levels being measured 30 minutes after dosing when treated with PROCYSBI.

A pivotal phase 3 randomized, crossover PK and PD study (which was also the first ever randomized study with immediate-release cysteamine bitartrate) demonstrated that at steady-state, patients receiving PROCYSBI every 12 hours (Q12H) maintained a comparable depletion of WBC cystine levels compared to immediate-release cysteamine bitartrate every 6 hours (Q6H). Forty-three (43) patients were randomized; twenty-seven (27) children (ages 6 to 12 years old), fifteen (15) adolescents (ages 12 to 21 years old) and one (1) adult with cystinosis and with native kidney function based on an estimated Glomerular Filtration Rate (GFR) (corrected for body surface area) > 30 mL/minute/1.73 m2 were randomized. Of those forty-three (43) patients, two (2) siblings withdrew at the end of the first crossover period, due to a prior planned surgery in one (1) of them; forty-one (41) patients completed the protocol. Two (2) patients were excluded from the per-protocol analysis because their WBC cystine level increased over 2 nmol hemicystine/mg protein during the immediate-release cysteamine treatment period. Thirty-nine (39) patients were included in the final primary per protocol efficacy analysis.

Per -Protocol (PP) Population (N=39)
	Immediate-release cysteamine bitartrate	PROCYSBI
WBC cystine level (LS Mean ± SE) in nmol hemicystine/mg protein*	0.44 ± 0.05	0.51 ± 0.05
Treatment effect (LS mean ± SE; 95.8% CI; p-value)	0.08 ± 0.03; 0.01 to 0.15; <0.0001
All Evaluable Patients (ITT) Population (N=41)
	Immediate-release cysteamine bitartrate	PROCYSBI
WBC cystine level (LS Mean ± SE) in nmol hemicystine/mg protein*	0.74 ± 0.14	0.53 ± 0.14
Treatment effect (LS mean ± SE; 95.8% CI; p-value)	–0.21 ± 0.14; –0.48 to 0.06; <0.001

* measured using the mixed leukocyte assay

Forty of forty-one (40/41) patients who completed the pivotal phase 3 study were entered in a prospective study with PROCYSBIthat stayed open as long as PROCYSBI could not be prescribed by their treating physician. In this study, the WBC cystine measured using the mixed leukocyte assay was always on average under optimal control at < 1 nmol hemicystine/mg protein. The estimated glomerular filtration rate (eGFR) did not change for the study population over time.

5.2 Pharmacokinetic properties

Absorption

The relative bioavailability is about 125% as compared to immediate-release cysteamine.

Food intake reduces the absorption of PROCYSBI at 30 minutes pre-dose (approximately 35% decrease in exposure) and at 30 min post-dose (approximately 16 or 45% decrease in exposure for intact and open capsules respectively). Food intake two hours after administration did not affect the absorption of PROCYSBI.

Distribution

The in vitro plasma protein binding of cysteamine, primarily to albumin, is approximately 54% and independent of plasma drug concentration over the therapeutic range.

Biotransformation

The elimination of unchanged cysteamine in the urine has been shown to range between 0.3% and 1.7% of the total daily dose in four patients; the bulk of cysteamine is excreted as sulphate.

In vitro data suggests that cysteamine bitartrate is likely to be metabolized by multiple CYP enzymes, including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1. CYP2A6 and CYP3A4 were not involved in the metabolism of cysteamine bitartrate under the experimental conditions.

Elimination

The terminal half-life of cysteamine bitartrate is approximately 4 hours.

Cysteamine bitartrate is not an inhibitor of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A4 in vitro.

In vitro : Cysteamine bitartrate is a substrate of P-gp and OCT2, but not a substrate of BCRP, OATP1B1, OATP1B3, OAT1, OAT3 and OCT1. Cysteamine bitartrate is not an inhibitor of OAT1, OAT3 and OCT2.

Special populations

The pharmacokinetics of cysteamine bitartrate has not been studied in special populations.

5.3 Preclinical safety data

In genotoxicity studies published for cysteamine, induction of chromosome aberrations in cultured eukaryotic cell lines has been reported. Specific studies with cysteamine did not show any mutagenic effects in the Ames test or any clastogenic effect in the mouse micronucleus test. A bacterial reverse mutation assay study (“Ames test”) was performed with the cysteamine bitartrate used for PROCYSBI and cysteamine bitartrate did not show any mutagenic effects in this test.

Reproduction studies showed embryo-foetotoxic effects (resorptions and post-implantation losses) in rats at the 100 mg/kg/day dose level and in rabbits receiving cysteamine 50 mg/kg/day. Teratogenic effects have been described in rats when cysteamine is administered over the period of organogenesis at a dose of 100 mg/kg/day.

This is equivalent to 0.6 g/m2/day in the rat, which is slightly less than the recommended clinical maintenance dose of cysteamine, i.e. 1.3 g/m2/day. A reduction of fertility was observed in rats at 375 mg/kg/day, a dose at which body weight gain was retarded. At this dose, weight gain and survival of the offspring during lactation was also reduced. High doses of cysteamine impair the ability of lactating mothers to feed their pups. Single doses of the drug inhibit prolactin secretion in animals.

Administration of cysteamine in neonate rats induced cataracts.

High doses of cysteamine, either by oral or parenteral routes, produce duodenal ulcers in rats and mice but not in monkeys. Experimental administration of the drug causes depletion of somatostatin in several animal species. The consequence of this for the clinical use of the drug is unknown.

No carcinogenic studies have been conducted with cysteamine bitartrate gastro-resistant hard capsules.

6. PHARMACEUTICAL PARTICULARS6.1 List of excipients

Capsule content

microcrystalline cellulose

methacrylic acid - ethyl acrylate copolymer (1:1)

hypromellose

talc

triethyl citrate

sodium lauryl sulphate

Capsule shell

gelatin

titanium dioxide (E171)

indigo carmine (E132)

Printing ink

shellac

povidone K-17

titanium dioxide (E171)

6.2 Incompatibilities

Not applicable.

6.3 Shelf life

24 months

In-use shelf life: 30 days.

6.4 Special precautions for storage

Store in a refrigerator (2°C-8°C). Do not freeze.

After opening do not store above 25°C.

Keep the container tightly closed in order to protect from light and moisture.

6.5 Nature and contents of container

PROCYSBI 25 mg hard capsule

50 mL white HDPE bottle containing 60 capsules with one 2-in-1 desiccant cylinder and one oxygen absorber cylinder, with a child resistant polypropylene closure.

Each bottle contains two plastic cylinders used for additional moisture and air protection. Please keep the two cylinders in each bottle during the use of the bottle. The cylinders may be discarded with the bottle after use.

PROCYSBI 75 mg hard capsule

400 mL white HDPE bottle containing 250 capsules with one 2-in-1 desiccant cylinder and two oxygen absorber cylinders, with a child resistant polypropylene closure.

Each bottle contains three plastic cylinders used for additional moisture and air protection.

Please keep the three cylinders in each bottle during the use of the bottle. The cylinders may be discarded with the bottle after use.

6.6 Special precautions for disposal

No special requirements.

7. MARKETING AUTHORISATION HOLDER

Chiesi Farmaceutici S.p.A.

Via Palermo 26/A

43122 Parma

Italy

8. MARKETING AUTHORISATION NUMBER(S)

PROCYSBI 25 mg hard capsule

EU/1/13/861/001

PROCYSBI 75 mg hard capsule

EU/1/13/861/002

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first authorisation: 06 September 2013

Date of latest renewal: 26 July 2018